US Sen. Tim Hutchinson, Newt Gingrich To Participate In BIO’s CEO & Investor Conference

WASHINGTON, D.C. (February 14, 2001) – U.S. Sen. Tim Hutchinson (R-Arkansas) and Newt Gingrich, former Speaker of the U.S. House of Representatives, will be featured with Carl B. Feldbaum, president of the Biotechnology Industry Organization (BIO), in a roundtable discussion on heath-care policy issues at BIO’s CEO & Investor Conference next week in New York.

BIO’s third annual CEO & Investor Conference, whose theme is“Investing in Biotechnology: The Value, The Risks, The Rewards,” will be held February 20-21 at the Waldorf Astoria Hotel in New York City.

Hutchinson, a member of the Senate Health, Education, Labor,and Pensions Committee, and Gingrich, CEO of the Gingrich Group and a senior fellow at the American Enterprise Institute, will appear with Feldbaum on a panel titled “The New Administration & the Biotech Industry” at 1:30 p.m. Tuesday, February 20.

Other keynote speakers at the two-day conference include Dr. Richard Klausner, director of the National Cancer Institute, and Dr. Nathan Myhrvold, co-founder of Intellectual Ventures and former chief technology officer of Microsoft Corporation. Klausner and Myhrvold are lunch speakers on Tuesday, February 20, and Wednesday, February 21, respectively. For more information on the conference and program visit wwww.investinbio.com

More than 1,500 biotech CEOs and investors are expected toattend the conference, which will include 12 investor sessions, 10 CEO roundtables and more than 90 company presentations. In addition, there will be an international reception and networking exhibition, which last year attracted more than 750 attendees and 40 exhibitors.

Cosponsors of the conference include AstraZeneca, Johnson & Johnson, IBM, SunMicrosystems, Nasdaq and 15 investment banks: Adam, Harkness & Hill, J.P. Morgan H&Q, Credit Suisse First Boston, Fortis Bank, Lazard, Lehman Brothers, Nomura, Prudential Vector Healthcare, Robertson Stephens, SG Cowen and Co., Salomon Smith Barney, Silicon Valley Bank, Thomas Weisel Partners, UBS Warburg and US Bancorp Piper Jaffray.

BIO represents more than 940 companies, academic institutionsand state biotechnology centers in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.

NOTE TO EDITORS: Registration for the news media is complimentary. Advance registration is encouraged. Please visit the Media section of the conference Web site http://www.investinbio.com. Reporters and editors must present valid press credentials onsite.

###